Future prospects for palliative care of mCRC

摘要: Abstract The last two decades have seen a transformation in the management of metastatic colorectal cancer (mCRC), as first irinotecan and later oxaliplatin, capecitabine three approved targeted therapies been added to 5-fluorouracil (5-FU) options for treatment this tumour. These developments brought with them significant improvement outlook many patients diagnosed mCRC, median overall survival (OS) has increased from approximately 12 months over 2 years. With continued high level interest searching new drugs regimens improving reflected large number studies undertaken, further improvements can be expected near future. Doublet chemotherapy is now accepted standard patients. Studies are currently investigating benefits using combinations cytotoxic agents well exploring impact that addition one or more combination on mCRC care. Promising results already reported phase III studies, although required determine best particular settings. In considering clinical setting, it may also relevant consider tailoring therapy individual patient, based presence absence biomarkers predictive response therapy. There much approach retrospective identified markers regimens. Prospective evaluate such their possible value clinic. It hoped will help improve